TP53BP1 and neoplasm: The hypothesis that reduction in 53BP1 expression is involved in the acquisition of cisplatin resistance is supported by the in silico finding that patients with the worst disease-free survival tend to show low expression of TP53BP1. This suggests a role for 53BP1 downregulation in tumor recurrence in a clinical setting.